One assignee leads the ranked field with 39 records, well ahead of the fifth-ranked company at 14 and the tenth at just 2. This gap indicates a single company has built a substantially larger portfolio than the rest of the 24 companies in the ranking. The long tail below the leader consists mostly of smaller filers, some with only a handful of records, so competitive monitoring should prioritise the top of the ranking rather than treat the field as evenly contested.

Filing activity peaked at 18 records in 2018 and has not returned to that level since. Between 2021 and 2024, the last year that can be treated as complete, filings held flat at 1 record in each year, a 0% change. Because publication typically lags filing by around 18 months, the lower counts visible in 2025 and 2026 reflect incomplete data rather than an actual drop in R&D activity, so the honest read is a steady, low-volume field rather than a declining one.

Material analysis and testing, IPC class G01N, covers 52.8% of the 142 records in scope, making it by far the most heavily claimed area. Control and regulating systems (G05B), medicinal preparations (A61K) and cosmetics use (A61Q) each account for roughly 11-13% of records, with enzyme- and DNA-based testing, digital transmission, data processing and wireless networking each below 10%. New filers should expect the densest prior art in material-analysis methods and comparatively more open space in the digital and connectivity-adjacent classes.